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We thank Drs Nosotti, Simone, and
Cioffi for their kind remarks and excel-
lent commentary regarding our recent
publication.1 Endobronchial ultrasound-
guided transbronchial needle aspiration
(EBUS-TBNA) is truly an emerging
technology that allows safe and accu-
rate assessment of the mediastinum
in patients with non–small cell lung
cancer. We also anticipate the results
of the ASTER trial2 with hopes that it
will further validate our findings.
We also understand the valid point
made regarding the utility of rapid on-
site evaluation during EBUS-TBNA.
To this end, recent studies have sought
to investigate the utility of rapid on-site
evaluation.3,4 However, in a practical
sense, it may not always be possible
to have access to the service of an
experienced cytopathologist at all
times during the performance of
EBUS-TBNA. Practice patterns ulti-
mately are developed with the re-
sources that are available within
a given institution.
Altogether, EBUS-TBNA provides
a safe and reliable method of assessing
the mediastinum in patients with non–
small cell lung cancer. Whether the
results are available instantaneously or
in a couple of days, what matters the
most is achieving an accurate result.
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CORONARYARTERY BYPASS
SURGERY: A ROLE OF
PLATELET FUNCTION
ASSESSMENT
To the Editor:
We read with great interest the re-
cently published systematic review
and meta-analysis of randomized trials
and observational studies by Biancari
and colleagues.1 When assessing the
influence of preoperative antiplatelet
therapy (APT) administration manage-
ment on bleeding and adverse ischemic
events, the objective quantification of
platelet activity should inextricably be
included in the considerations. Ex-
pected inhibition of platelet function
is not always achieved after APT
administration. The frequency of low
responsiveness to aspirin and clopidog-
rel has been reported to range from 1%
to 45% for the 2 drugs.2 The efficacy of
platelet inhibition with aspirin and clo-
pidogrel varies widely among patients,
from intensive platelet inhibition to
poor platelet response. The effect of
clopidogrel on bleeding mainly de-
pends on2 factors: (1) observedplatelet
inhibition, which depends on inherent
platelet activity before clopidogrel
administration and platelet inhibitory
response to clopidogrel, and (2) the
ability of newborn platelets to restore
normal aggregation after clopidogrelardiovascular Surgery c July 2012discontinuation. This results in individ-
ual widespread variability in the activ-
ity of adenosine diphosphate platelet
receptors, which consequently reflects
similar variability in proclivity to ex-
cessive bleeding or adverse ischemic
events. Awidi and colleagues3 found
that the combination of aspirin and
clopidogrel had greater inhibitory
effects on platelet aggregation than ei-
ther agent alone. There is evidence
that certain patients have an accentu-
ated response to the usual doses of pre-
operative aspirin that may result in
increased perioperative blood loss.4
Therefore, the benefits and risks of us-
ing clopidogrel before coronary artery
bypass grafting (CABG) should be in-
dividually assessed according to plate-
let function tests, and the role of
aspirin should inevitably be included
in the considerations. For patients re-
ceiving dual APT (aspirinþ clopidog-
rel) before CABG, the influence of
aspirin on bleeding and ischemic ad-
verse events should be examined sepa-
rately using anaspirin-sensitive platelet
function test. The role of aspirin and
clopidogrel should be assessed sepa-
rately by drug-specific platelet func-
tion tests to provide the most precise
and reliable information on the benefits
and risks of preoperative administra-
tion for each antiplatelet agent, thus
facilitating an individual approach to
patients with the aim of reducing
bleeding and adverse ischemic events.
Evaluation of the effect ofAPT (aspirin
or clopidogrel) on both bleeding and is-
chemic events should be based on
platelet function assessment with sub-
sequent distinction of patients with
high residual platelet activity, thus
a proclivity to ischemic events, or
enhanced platelet inhibition, thus a pro-
clivity to excessive bleeding. Thegroup
of patients with pronounced platelet in-
hibition observed during APT could
benefit from early preoperative APT
withdrawal in terms of excessive bleed-
ing prevention. For patients undergoing
CABG, individually tailored APT ad-
ministration management based on
platelet function tests, both pre- and
